Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) FCF Margin % : 22.60% (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Regeneron Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $776 Mil. Regeneron Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3,434 Mil. Therefore, Regeneron Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 22.60%.

As of today, Regeneron Pharmaceuticals's current FCF Yield % is 3.77%.

The historical rank and industry rank for Regeneron Pharmaceuticals's FCF Margin % or its related term are showing as below:

REGN' s FCF Margin % Range Over the Past 10 Years
Min: 14.88 Med: 25.75 Max: 40.63
Current: 27.96

During the past 13 years, the highest FCF Margin % of Regeneron Pharmaceuticals was 40.63%. The lowest was 14.88%. And the median was 25.75%.

REGN's FCF Margin % is ranked better than
93.7% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs REGN: 27.96

Regeneron Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Regeneron Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals FCF Margin % Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

30.51

23.58

40.63

27.91

27.96

Regeneron Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															42.99	34.42	28.13	27.19	22.60

Competitive Comparison of Regeneron Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Regeneron Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's FCF Margin % falls into.

Regeneron Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Regeneron Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	3667.6	/	13117.2
	=	27.96 %

Regeneron Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	776.2	/	3434.3
	=	22.60 %

Regeneron Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

REGN:Mexico RGO:Germany RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Executives

Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan	director	CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos	director, officer: President and CSO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt	officer: SVP Commercial	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown	director
Christopher R. Fenimore	officer: VP, Controller	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy	officer: EVP Research	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini	director	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P	officer: EVP & General Mgr Industrial O	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry	officer: SVP Fin, Dep CFO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl	officer: SVP, Preclinical Development	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein	director	DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390